By Fineline Cube 
Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736 billion, representing a 3% year-over-year increase at constant exchange rates (CER). The company’s Growth Portfolio generated USD 1.06 billion in revenue, up 24% year-over-year, demonstrating strong momentum across its diversified pipeline of innovative therapies.
Financial Performance Snapshot
| Metric | Q2 2026 | YoY Change (CER) |
|---|---|---|
| Total Revenue | USD 2.736B | +3% |
| Growth Portfolio Revenue | USD 1.06B | +24% |
| Growth Portfolio Contribution | 39% of total revenue | Significant expansion |
Growth Portfolio Detailed Performance
Neurology & Rare Disease Leaders
- SPINRAZA (nusinersen): USD 402M (+2% YoY)
- Primary driver: High-dose regimen adoption exceeding expectations across all launched regions
- Indication: Spinal muscular atrophy (SMA)
- LEQEMBI (lecanemab): USD 184M (+15% YoY)
- U.S. sales: USD 97M with continued sequential growth
- Regulatory milestone: FDA approval of LEQEMBI IQLIK for at-home initiation (first-of-its-kind anti-amyloid treatment)
- Indication: Early Alzheimer’s disease
- SKYCLARYS: USD 168M (+29% YoY)
- Primary driver: Global demand growth from ongoing commercial launches in Europe and international markets
- Indication: Friedreich’s ataxia
Recent Launch Success Stories
- ZURZUVAE: USD 71M (+53% YoY)
- Geographic expansion: First commercial launch outside U.S. in Germany
- Significance: Marks initial international rollout for postpartum depression (PPD) treatment
- SYFOVRE: USD 162M (+8% YoY)
- Performance milestone: Strongest quarterly demand since launch
- Acquisition impact: USD 97M recognized following Apellis acquisition close on May 14, 2026
- Indication: Geographic atrophy (GA) secondary to age-related macular degeneration
- EMPAVELI: USD 46M (+123% YoY)
- Acquisition contribution: USD 30M recognized by Biogen post-Apellis acquisition
- Indication: Paroxysmal nocturnal hemoglobinuria (PNH)
Portfolio Challenges
- VUMERITY: USD 197M (-7% YoY)
- Context: Impact from inventory dynamics despite 7% first-half growth
- Indication: Multiple sclerosis (MS)
Strategic Acquisition Integration
The Apellis Pharmaceuticals acquisition, completed on May 14, 2026, has immediately contributed to Biogen’s growth trajectory:
- SYFOVRE: USD 97M in Q2 revenue recognition
- EMPAVELI: USD 30M in Q2 revenue recognition
- Portfolio diversification: Enhanced presence in ophthalmology and rare hematology
- Integration status: Successful operational integration enabling immediate commercial contribution
Market Dynamics & Competitive Positioning
Alzheimer’s Disease Leadership
- LEQEMBI differentiation: At-home initiation capability provides significant patient convenience advantage
- Market expansion: Continued U.S. growth with potential international opportunities
- Competitive moat: First-mover advantage in anti-amyloid space with innovative delivery model
Global Commercial Execution
- International success: Strong performance in European and global markets across multiple products
- Launch excellence: Effective commercial execution for recent product introductions
- Geographic diversification: Reduced dependency on U.S.-only revenue streams
Therapeutic Area Breadth
- Neurology dominance: Continued leadership in SMA, MS, and Alzheimer’s disease
- Rare disease expansion: Growing footprint in Friedreich’s ataxia, PPD, and PNH
- Ophthalmology entry: New presence in geographic atrophy through Apellis acquisition
Forward Outlook & Strategic Priorities
- Growth Portfolio acceleration: On track to exceed full-year guidance based on H1 momentum
- LEQEMBI commercial expansion: At-home initiation expected to drive further adoption
- International launch pipeline: Multiple products in various stages of global rollout
- Integration benefits: Full-year contribution from Apellis assets expected in H2 2026
- Pipeline catalysts: Additional regulatory submissions and commercial launches anticipated
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, regulatory approvals, and commercial launches. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market access, and integration challenges.-Fineline Info & Tech